FSGS
73 programs · 72 companies
Programs
73
Companies
72
Trials
45
MOAs
44
BCL-2iHER2STINGagAnti-TauBTKiTROP-2 ADCPLK4iCl18.2GLP-1/GIPSHP2i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-3592 | Phase 1/2 | GIP-R | ||
| SNY-7254 | Phase 2 | CFTR | ||
| SNY-5894 | Approved | CFTR | ||
| NVO-9630 | Phase 2 | CD3 | ||
| TAK-2403 | Phase 2 | WEE1 | ||
| BAY-6520 | Phase 2 | AHR | ||
| AMG-2597 | Phase 2/3 | CD38 | ||
| Elrarapivir | Phase 1 | GIP-R | ||
| Pemiinavolisib | NDA/BLA | CD47 | ||
| Talatapinarof | Phase 1/2 | PCSK9 | ||
| Surarasimod | Phase 2 | SHP2 | ||
| MRU-8112 | Preclinical | PD-L1 | ||
| Terazumab | Phase 2 | BTK | ||
| SLR-4773 | Preclinical | SHP2 | ||
| Bemainavolisib | NDA/BLA | PRMT5 | ||
| Capirelsin | Phase 2 | FLT3 | ||
| EXA-4696 | Phase 2/3 | KRASG12C | ||
| Zenozasiran | Preclinical | BET | ||
| 450-6746 | Approved | PD-1 | ||
| Rimatuximab | Phase 2/3 | PLK4 | ||
| Zanunaritide | Phase 1/2 | TNFα | ||
| NIA-IIT-407 | Phase 2 | CD38 | ||
| EOR-IIT-940 | Phase 3 | PCSK9 | ||
| Suraosocimab | Phase 1 | PSMA | ||
| MOR-7494 | Phase 1 | SMN2 | ||
| Pemizasiran | Phase 1/2 | MDM2 | ||
| TES-3466 | NDA/BLA | GLP-1R | ||
| Voxazanubrutinib | Preclinical | GLP-1R | ||
| Zoriosocimab | Approved | AHR | ||
| THI-6273 | Phase 2 | CD19 | ||
| Pexasertib | Preclinical | CD38 | ||
| Polazasiran | Phase 3 | KIF18A | ||
| RAP-8975 | Phase 2 | TROP-2 | ||
| Nidarapivir | Phase 1/2 | IL-13 | ||
| CN-8014 | Phase 2/3 | Aβ | ||
| Rimabrutinib | Preclinical | FXIa | ||
| MEI-6717 | Phase 2 | CDK2 | ||
| Lisozanubrutinib | Approved | EGFR | ||
| OBS-1037 | Preclinical | MDM2 | ||
| BIV-3779 | Phase 2/3 | IL-17A | ||
| Sovainavolisib | NDA/BLA | PI3Kα | ||
| NTR-7700 | Phase 1/2 | Nectin-4 | ||
| ADA-3632 | NDA/BLA | BET | ||
| MEI-1324 | Preclinical | KRASG12C | ||
| Zanuratamab | Phase 1 | TIM-3 | ||
| LAU-4167 | NDA/BLA | AHR | ||
| Gelizumab | Phase 1/2 | PI3Kα | ||
| GLO-6047 | Preclinical | CD47 | ||
| Mavulemzoparlimab | Phase 3 | FXIa | ||
| TCB-6877 | Phase 1/2 | GPRC5D | ||
| Talatinib | Phase 2 | Aβ | ||
| BER-3725 | Phase 3 | FXIa | ||
| Zanurapivir | Phase 2 | CD47 | ||
| Elracagene | NDA/BLA | GLP-1R | ||
| Gelizasiran | Phase 2/3 | CDK2 | ||
| Fixabrutinib | Phase 1 | MET | ||
| GRF-2905 | Phase 1 | Menin | ||
| Talaosocimab | Phase 1 | RET | ||
| Ivozasiran | Phase 1/2 | Tau | ||
| Teratenlimab | Preclinical | TYK2 | ||
| ACH-2340 | Phase 3 | CDK4/6 | ||
| BIO-9702 | Phase 1 | SOS1 | ||
| BIO-8234 | Preclinical | JAK2 | ||
| PHA-5173 | Phase 3 | TIGIT | ||
| VIN-1694 | Approved | AuroraA | ||
| INS-IIT-513 | Phase 3 | CD47 | ||
| Pemicagene | Approved | IL-13 | ||
| Elrazanubrutinib | NDA/BLA | APOC3 | ||
| Ribotapinarof | Phase 2 | WRN | ||
| Talazanubrutinib | Phase 1/2 | EGFR | ||
| Liramavacamten | Phase 1 | CD38 | ||
| Tezevorutinib | Preclinical | GPRC5D | ||
| PAH-7465 | Phase 2 | CD3 |
Trials (45)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04557181 | RHH-3592 | Phase 1/2 | Recruiting |
| NCT03420093 | RHH-3592 | Phase 1/2 | Terminated |
| NCT08766709 | SNY-7254 | Phase 2 | Not yet recr... |
| NCT07214747 | SNY-5894 | Approved | Active |
| NCT06012489 | BAY-6520 | Phase 2 | Completed |
| NCT04364972 | Talatapinarof | Phase 1/2 | Completed |
| NCT04647345 | Surarasimod | Phase 2 | Terminated |
| NCT05871806 | SLR-4773 | Preclinical | Terminated |
| NCT08874452 | EXA-4696 | Phase 2/3 | Not yet recr... |
| NCT08519644 | Zenozasiran | Preclinical | Not yet recr... |
| NCT07917540 | 450-6746 | Approved | Not yet recr... |
| NCT08715152 | Zanunaritide | Phase 1/2 | Completed |
| NCT03342072 | NIA-IIT-407 | Phase 2 | Not yet recr... |
| NCT08853348 | EOR-IIT-940 | Phase 3 | Not yet recr... |
| NCT05446919 | Suraosocimab | Phase 1 | Terminated |
| NCT04118402 | Pemizasiran | Phase 1/2 | Active |
| NCT04421497 | TES-3466 | NDA/BLA | Active |
| NCT06957524 | Zoriosocimab | Approved | Not yet recr... |
| NCT03336725 | Polazasiran | Phase 3 | Recruiting |
| NCT04103924 | RAP-8975 | Phase 2 | Not yet recr... |